LAGIPRA peptide TFA is a long-actingGIP1Ragonist. LAGIPRA peptide TFA enhancesinsulinsensitivity by augmenting glucose disposal and reduces branched-chainamino acids(BCAAs) and ketoacids. LAGIPRA peptide TFA has the potential for the research of type 2 diabetes[1].
References:
[1].Samms RJ, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest. 2021 Jun 15;131(12):e146353.
LAGIPRA peptide TFA 是一种长效的GIP1R激动剂。LAGIPRA peptide TFA 通过增强葡萄糖处理来增强胰岛素敏感性，减少循环中的支链氨基酸 (BCAA) 和酮酸。LAGIPRA peptide TFA 具有用于 2 型糖尿病研究的潜力。